Search - tctmd.com

Displaying 301 - 320 of 900

Sort: Relevancy | Date

Presentation TCT 2017

The High-Bleeding-Risk Patient: Physician-Scientist Perspectives on Appropriate Patients and DAPT Duration

Presenter: Mitchell W. Krucoff, P.F. Adrian Magee, Marie-Claude Morice

October 31, 2017

Presentation TCT 2017

Rationale and Studies of P2Y12 Inhibitor Monotherapy

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Roxana Mehran

October 30, 2017

Presentation TCT 2017

Utility of Genotyping and Platelet Function Testing to Guide Antiplatelet Therapy: 2017 Assessment

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Thomas Engstroem

October 30, 2017

Presentation TCT 2017

Switching to and From Cangrelor: When and How?

Presenter: Dominick J. Angiolillo, Marco Valgimigli

October 30, 2017

Presentation TCT 2017

Switching Between Oral P2Y12 Receptor Inhibitors: When and How?

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Matthew J. Price

October 30, 2017

Presentation TCT 2017

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Fabiana Rollini

October 30, 2017

Presentation TCT 2017

Impact of Race and Sex on Platelet Reactivity and Clinical Implications

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Ron Waksman

October 30, 2017

Presentation TCT 2017

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? No, Based on HORIZONS-AMI, PLATO, PEGASUS, and Other Studies!

Presenter: John A. Bittl, Freek W.A. Verheugt, Gennaro Giustino

October 30, 2017

Presentation TCT 2017

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? Yes, Based on TROPICAL-ACS, TRITON, and Other Studies!

Presenter: John A. Bittl, Freek W.A. Verheugt, Dirk Sibbing

October 30, 2017

Presentation TCT 2017

DAPT Duration After BVS: Can Evidence-Based Recommendations Be Made?

Presenter: John A. Bittl, Freek W.A. Verheugt, Davide Capodanno

October 30, 2017

Presentation TCT 2017

Debate: DAPT Duration With Contemporary DES: Short (<1 Year) DAPT for Most ACS Patients!

Presenter: John A. Bittl, Freek W.A. Verheugt, Marco Valgimigli

October 30, 2017

Presentation TCT 2017

Topic 2: Outcomes Without a Clear Mechanism (Radial Mortality Benefit, Aspirin/Ticagrelor Interaction, and More)

Presenter: Robert A. Byrne, Gregg W. Stone, Robert A. Harrington

October 30, 2017

Presentation TCT 2017

Debate: DAPT Duration With Contemporary DES: Prolonged (>1 Year) DAPT for Most ACS Patients!

Presenter: John A. Bittl, Freek W.A. Verheugt, Robert W. Yeh

October 30, 2017

Presentation TCT 2017

Predicting The Future: Will the Ongoing DES 3-Month DAPT Studies With Synergy and Xience Change How We Treat High Risk Bleeding Patients?

Presenter: C. Michael Gibson, Stephan Windecker

October 30, 2017

Presentation TCT 2017

Predicting the Future: Will the Ongoing TWILIGHT and GLOBAL LEADERS Trials Change The Current Recommended Approach to Chronic Antiplatelet Therapy?

Presenter: C. Michael Gibson, Stephan Windecker, Eric R. Bates

October 30, 2017

Presentation TCT 2017

Interventional Pharmacology Strategies for PCI and ACS

Presenter: Joseph P. Carrozza Jr, Jose M. Wiley, Piera Capranzano

October 29, 2017

Presentation TCT 2017

Interventional Pharmacology: A Guideline-based Review

Presenter: Jose de Ribamar Costa Jr, Jose L. Leiva-Pons, Dominick J. Angiolillo

October 29, 2017

Presentation TCT 2017

Patients First Encounter, Tele-medicine and Interventional Approach

Presenter: Jose de Ribamar Costa Jr, Jose L. Leiva-Pons, Jamil Cade

October 29, 2017

Presentation TCT 2017

DAPT Duration: Individualized vs Generalized Approach

Presenter: Jeroen J. Bax, Michael A. Borger, Stephan Windecker, Marco Valgimigli

October 29, 2017

Presentation TCT 2017

Consideration of Prolonged DAPT After DES Deployment From Angioscopic Findings

Presenter: Takeshi Kimura, Shigeru Saito, Takafumi Ueno

October 29, 2017

Advertisement

The High-Bleeding-Risk Patient: Physician-Scientist Perspectives on Appropriate Patients and DAPT Duration

Rationale and Studies of P2Y12 Inhibitor Monotherapy

Utility of Genotyping and Platelet Function Testing to Guide Antiplatelet Therapy: 2017 Assessment

Switching to and From Cangrelor: When and How?

Switching Between Oral P2Y12 Receptor Inhibitors: When and How?

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Impact of Race and Sex on Platelet Reactivity and Clinical Implications

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? No, Based on HORIZONS-AMI, PLATO, PEGASUS, and Other Studies!

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? Yes, Based on TROPICAL-ACS, TRITON, and Other Studies!

DAPT Duration After BVS: Can Evidence-Based Recommendations Be Made?

Debate: DAPT Duration With Contemporary DES: Short (<1 Year) DAPT for Most ACS Patients!

Topic 2: Outcomes Without a Clear Mechanism (Radial Mortality Benefit, Aspirin/Ticagrelor Interaction, and More)

Debate: DAPT Duration With Contemporary DES: Prolonged (>1 Year) DAPT for Most ACS Patients!

Predicting The Future: Will the Ongoing DES 3-Month DAPT Studies With Synergy and Xience Change How We Treat High Risk Bleeding Patients?

Predicting the Future: Will the Ongoing TWILIGHT and GLOBAL LEADERS Trials Change The Current Recommended Approach to Chronic Antiplatelet Therapy?

Interventional Pharmacology Strategies for PCI and ACS

Interventional Pharmacology: A Guideline-based Review

Patients First Encounter, Tele-medicine and Interventional Approach

DAPT Duration: Individualized vs Generalized Approach

Consideration of Prolonged DAPT After DES Deployment From Angioscopic Findings

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content